Holtz David, Ramondetta Lois M, Burke Thomas W, Palazzo Juan P, Dunton Charles J, Atkinson E Neely, Broaddus Russell R
Thomas Jefferson University, 111S 11th Street, 620 Gibbon Building, Department of Obstetrics and Gynecology, Philadelphia, PA 19107, USA.
Anticancer Res. 2002 Sep-Oct;22(5):2945-8.
Tamoxifen is associated with increased rates of endometrial hyperplasia and adenocarcinoma. Our previous work suggested tamoxifen-associated endometrial cancers might be associated with p53 mutations. PTEN, a tumor suppressor gene, is altered in low-grade endometrial carcinoma. This study evaluates PTEN immunohistochemical (IHC) expression in tamoxifen-associated endometrial cancers.
Twenty-eight endometrial carcinoma specimens were examined from patients with a history of breast cancer. Patients who had taken Tamoxifen (15) were compared to non-users (13). IHC staining was performed for PTEN; overexpression was defined as greater than 70% positivity.
The mean duration of tamoxifen use was 3.3 years (3-171 months). Four out of 15 (27%) tamoxifen users expressed PTEN compared with 2 out of 13 (15%) of non-users.
In this study, it appears that tamoxifen-associated endometrial cancers are not significantly different from sporadic endometrial cancer with regards to PTEN IHC expression, although there is a trend towards retained PTEN expression.
他莫昔芬与子宫内膜增生和腺癌的发生率增加有关。我们之前的研究表明，他莫昔芬相关的子宫内膜癌可能与p53突变有关。PTEN是一种肿瘤抑制基因，在低级别子宫内膜癌中会发生改变。本研究评估PTEN在他莫昔芬相关子宫内膜癌中的免疫组化（IHC）表达。
对28例有乳腺癌病史的子宫内膜癌标本进行检查。将服用他莫昔芬的患者（15例）与未服用者（13例）进行比较。对PTEN进行IHC染色；过表达定义为阳性率大于70%。
他莫昔芬的平均使用时间为3.3年（3 - 171个月）。15例服用他莫昔芬的患者中有4例（27%）表达PTEN，而13例未服用者中有2例（15%）表达PTEN。
在本研究中，就PTEN IHC表达而言，他莫昔芬相关的子宫内膜癌似乎与散发性子宫内膜癌没有显著差异，尽管存在PTEN表达保留的趋势。
Zotero 插件